Profile data is unavailable for this security.
About the company
WuXi XDC Cayman Inc is a holding company primarily engaged in the provision of contract research, development and manufacturing services (CRDMO) for antibody drug conjugates (ADCs) and a wider range of bioconjugate drugs. The Company conducts its businesses through two segments. Research Services on Fee-for-service(FFS) Basis segment providing research services to its customers through FFS contracts. The Research Services on Full-time-equivalent(FTE) Basis segment providing a project team of employees dedicated to the customer's studies for a specific period of time. Based on biopharmaceuticals and small molecule drugs, the Company also provides comprehensive cross-domain services, covering the discovery, process development and good manufacturing practice (GMP) production of bioconjugated drugs, linkers and payloads. The Company conducts its business in domestic and foreign markets.
- Revenue in HKD (TTM)2.30bn
- Net income in HKD306.49m
- Incorporated2020
- Employees1.18k
- LocationWuXi XDC Cayman IncNo. 11 Xinhui Ring Road, Xinwu DistrictWUXI KY1-1104ChinaCHN
- Websitehttps://wuxixdc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Henlius Biotech Inc | 5.83bn | 590.23m | 10.24bn | 3.64k | 17.40 | 4.32 | 10.46 | 1.76 | 1.08 | 1.08 | 10.68 | 4.36 | 0.5731 | 1.95 | 9.10 | 1,603,434.00 | 5.80 | -8.59 | 12.47 | -14.14 | 72.64 | 71.77 | 10.12 | -27.37 | 0.3786 | 6.48 | 0.6512 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
| SciClone Pharmaceuticals (Holdings) Ltd | 3.41bn | 1.21bn | 11.63bn | 1.05k | 9.93 | 3.17 | 8.49 | 3.41 | 1.86 | 1.86 | 5.24 | 5.85 | 0.7585 | 3.56 | 3.83 | 3,248,665.00 | 26.97 | 27.09 | 33.34 | 36.32 | 74.67 | 76.06 | 35.55 | 35.43 | 4.50 | 33.70 | 0.01 | 22.98 | 14.76 | 17.50 | 31.16 | 15.96 | 25.65 | -- |
| SSY Group Ltd | 6.46bn | 1.32bn | 13.98bn | 5.60k | 10.64 | 2.02 | 8.00 | 2.16 | 0.4427 | 0.4427 | 2.17 | 2.33 | 0.5637 | 3.00 | 3.01 | 1,154,109.00 | 11.59 | 10.51 | 15.58 | 14.03 | 56.01 | 58.72 | 20.57 | 18.62 | 1.60 | 29.61 | 0.317 | 38.56 | 0.4505 | 9.10 | 17.44 | 7.66 | 3.94 | 13.56 |
| Zai Lab Ltd | 2.28bn | -2.65bn | 14.52bn | 2.18k | -- | 2.39 | -- | 6.38 | -2.74 | -2.74 | 2.35 | 6.12 | 0.2697 | 2.84 | 5.61 | -- | -31.41 | -37.72 | -36.81 | -42.72 | 62.86 | 64.75 | -116.45 | -282.44 | 4.43 | -- | 0.0596 | -- | 24.03 | 360.03 | 24.51 | -- | -3.45 | -- |
| 3SBio Inc | 8.45bn | 1.67bn | 14.88bn | 5.41k | 9.04 | 0.9645 | 7.16 | 1.76 | 0.6749 | 0.6749 | 3.46 | 6.32 | 0.3426 | 1.58 | 7.01 | 1,561,399.00 | 6.95 | 7.44 | 9.03 | 9.29 | 84.98 | 82.91 | 20.30 | 21.50 | 2.26 | 22.72 | 0.2266 | -- | 13.84 | 11.26 | -19.13 | 3.94 | 8.78 | -- |
| Simcere Pharmaceutical Group Ltd | 7.14bn | 772.63m | 15.29bn | 7.03k | 20.22 | 1.96 | 13.82 | 2.14 | 0.2899 | 0.2899 | 2.74 | 2.98 | 0.6106 | 3.53 | 2.65 | 1,016,477.00 | 6.60 | 10.17 | 8.94 | 15.60 | 75.43 | 78.82 | 10.80 | 17.50 | 1.87 | 0.9742 | 0.1652 | 46.68 | 4.49 | 7.92 | -23.22 | -0.5213 | 23.93 | -- |
| The United Laboratories Intl. Hldgs Ltd. | 14.85bn | 2.92bn | 16.35bn | 15.00k | 5.60 | 1.19 | 4.63 | 1.10 | 1.61 | 1.61 | 8.17 | 7.58 | 0.6871 | 3.36 | 6.15 | 990,152.40 | 13.51 | 7.89 | 20.52 | 12.64 | 46.11 | 44.17 | 19.66 | 12.73 | 1.74 | -- | 0.1055 | 28.99 | 21.22 | 12.84 | 70.85 | 31.66 | 24.19 | 14.67 |
| Grand Pharmaceutical Group Ltd | 10.53bn | 1.88bn | 17.50bn | 10.53k | 9.20 | 1.14 | 7.65 | 1.66 | 0.5356 | 0.5356 | 3.00 | 4.33 | 0.4692 | 2.94 | 10.26 | 999,581.40 | 8.45 | 10.09 | 11.66 | 14.01 | 61.96 | 61.97 | 18.00 | 22.35 | 0.9819 | 22.96 | 0.1831 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
| WuXi XDC Cayman Inc | 2.30bn | 306.49m | 18.35bn | 1.18k | 54.69 | 3.11 | 49.54 | 7.99 | 0.2801 | 0.2801 | 2.13 | 4.92 | -- | -- | -- | 1,948,887.00 | -- | -- | -- | -- | 26.35 | -- | 13.35 | -- | 4.03 | -- | 0.0005 | -- | 114.44 | -- | 82.07 | -- | -- | -- |
| China Traditional Chinese Med Hldg CoLtd | 19.59bn | 1.39bn | 21.25bn | 17.30k | 15.30 | 0.9291 | 7.87 | 1.08 | 0.2759 | 0.2759 | 3.89 | 4.54 | 0.4985 | 1.47 | 2.16 | 1,132,118.00 | 3.84 | 4.60 | 5.85 | 7.07 | 51.18 | 57.07 | 7.70 | 9.77 | 1.48 | 9.83 | 0.1773 | 17.35 | 26.69 | 9.99 | 68.11 | -2.24 | -12.75 | -- |
| Genscript Biotech Corp | 6.56bn | -746.37m | 21.26bn | 6.94k | -- | 1.95 | -- | 3.24 | -0.3543 | -0.3543 | 3.11 | 5.13 | 0.283 | 7.59 | 5.45 | 946,064.60 | -11.97 | -18.34 | -18.27 | -26.15 | 48.78 | 54.68 | -42.30 | -64.91 | 4.65 | -- | 0.1694 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
| RemeGen Co Ltd | 1.16bn | -1.63bn | 22.13bn | 3.62k | -- | 3.67 | -- | 19.03 | -3.03 | -3.03 | 2.16 | 6.91 | 0.1864 | 0.4005 | 4.31 | 321,785.80 | -26.17 | -18.66 | -31.75 | -23.75 | 76.48 | 81.94 | -140.43 | -102.88 | 1.31 | -64.32 | 0.2682 | -- | 40.16 | 148.65 | -51.30 | -- | 59.07 | -- |
| HUTCHMED (China) Ltd | 6.55bn | 787.83m | 25.66bn | 1.99k | 32.79 | 4.49 | 30.03 | 3.92 | 0.8982 | 0.8982 | 7.62 | 6.55 | 0.7258 | 7.19 | 7.69 | 3,295,216.00 | 8.76 | -14.35 | 13.36 | -20.43 | 54.12 | 36.57 | 12.06 | -31.44 | 2.60 | -- | 0.1038 | -- | 96.52 | 31.38 | 127.93 | -- | 38.65 | -- |
Data as of May 31 2024. Currency figures normalised to WuXi XDC Cayman Inc's reporting currency: Hong Kong Dollar HKD
8.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invesco Advisers, Inc.as of 16 Nov 2023 | 37.97m | 3.17% |
| UBS Asset Management (Singapore) Ltd.as of 16 Nov 2023 | 15.19m | 1.27% |
| UBS Asset Management (Hong Kong) Ltd.as of 28 Mar 2024 | 15.10m | 1.26% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 9.79m | 0.82% |
| Fidelity Management & Research (Hong Kong) Ltd.as of 31 Mar 2024 | 8.69m | 0.73% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 7.75m | 0.65% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.84m | 0.24% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 993.60k | 0.08% |
| Harvest Global Investments Ltd.as of 31 Dec 2023 | 906.84k | 0.08% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2024 | 759.00k | 0.06% |
More ▼
Data from 31 Dec 2023 - 22 May 2024Source: FactSet Research Systems Inc.
